monthly gross salary of at least EUR 3.945,90 (following the recommendations of FWF): CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: The REsolution consortium is looking for a project scientist to study the functional impact of genetic variations..... Vienna (AT)

monthly gross salary of at least EUR 3.945,90 (following the recommendations of FWF): CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: Do you want to be part of a very large multidisciplinary effort committed to understand human membrane..... Vienna (AT)

Funding Opportunity RFA-NS-22-027 from the NIH Guide for Grants and Contracts. (Reissue of RFA-NS-18-014 and RFA-NS-21-014) This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted Brain Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-22-026). Applications should be exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.

Notice NOT-AT-22-013 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: An exciting opportunity has been created for a scientific software engineer to work on the development of the ChEBI database (https://www.ebi.ac.uk/ch Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: We are looking for an innovative technical engineer who can help develop and deploy the workflow and data infrastructure that is becoming increasingly Hinxton, Cambridgeshire, England

Funding Opportunity RFA-NS-22-035 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, approaches to biomedical research education and mentoring that will keep pace with the rapid evolution of the research enterprise. This NIH Neuroscience Doctoral Readiness Program (DR Program) expects that the proposed research education programs will incorporate extensive research experiences within the NINDS mission and well-designed courses for skills development and education to prepare recent baccalaureates from diverse backgrounds to transition into and complete rigorous, research-focused doctoral degree programs (e.g., Ph.D. or M.D./Ph.D.) in biomedical fields. This is a limited competition funding opportunity announcement to support postbaccalaureate programs that will be affiliated with a funded NIH T32 program. Eligibility is limited to PD(s)/PI(s) or MPI teams that include at least one PD/PI of a grant supported by the following FOAs: T32 - Jointly Sponsored Institutional Predoctoral Training Program (JSPTPN), PAR-20-076;NINDS T32 - Institutional Research Training Grant, PAR-21-149; or NINDS T32 - Institutional Translational Research Training Program, PAR-19-228. In all cases, a PD/PI of the T32 grant from a FOA cited above, must be the PD/PI or an MPI of this R25. This Funding Opportunity Announcement (FOA) does not allow appointed participants to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

Funding Opportunity RFA-CA-22-014 from the NIH Guide for Grants and Contracts. The purpose of this solicitation is to fund a Data, Evaluation and Coordinating Center (DECC) that will support the data and evaluation activities and coordinate a learning collaborative related to the CUSP2CT program (companion RFA CA-21-057).

Notice NOT-OD-22-074 from the NIH Guide for Grants and Contracts

Notice NOT-EB-22-003 from the NIH Guide for Grants and Contracts

Notice NOT-EY-22-011 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-22-015 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to advance research to discover and validate novel biomarkers of Tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.

Notice NOT-NS-22-072 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-071 from the NIH Guide for Grants and Contracts

Notice NOT-NR-22-010 from the NIH Guide for Grants and Contracts

Notice NOT-MD-22-010 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-22-050 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials.The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology. Applications to identify biomarkers or biomarker signatures that predict or monitor a therapeutic response across several related pain conditions should feature Multiple Principal Investigator (MPI)-led teams that represent each of the related pain conditions and associated clinical networks. The MPI-led teams are expected to decide upon a single set of measures or biomarker modalities (i.e., combination of omics, QST, actigraphy, EEG, digital measures, etc.) as components of the biosignature for all pain conditions represented in the application. Applications should feature centralized resource groups that will coordinate clinical trials and standardize all sample or data collection methods, technology development, statistical analysis and algorithm development across the pain conditions under investigation. Applications seeking to develop biomarkers or biomarker signatures that will be used to predict and/or monitor a therapeutic response for a single pain condition must also feature MPI-led teams that represent the cross functional expertise necessary for biomarker and/or signature development, along with the same types of centralized resource groups that coordinate clinical trials and standardize sample or data collection methods, technology development and statistical analysis.

Notice NOT-NS-22-066 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-110 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-085 from the NIH Guide for Grants and Contracts